Health
Pancreatitis drug blocks SARS-CoV-2 activators in the upper respiratory tract – News-Medical.Net
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed…
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development.
The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells.
However, it was previously…
-
General17 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
Noosa News21 hours agoMeet Llew O’Brien, LNP | Noosa Today
-
Noosa News18 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer
-
General15 hours agoNew Zealand wants more ‘automated decision-making’ in its welfare system. Could that lead to Robodebt 2.0?